News Sentiment

NBIX sentiment intelligence

Neurocrine Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 177.11 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+1.6% over one week, +10.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball

Market Reaction

Balanced read

68/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction 1.6% Price digesting
Trend fit Trend active 10.9% over four weeks
Fair value 35.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 24
Neutral 23
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 7
ChartMill 3
Investing.com 3
Moomoo 3
TradingView 3
Ad Hoc News 3
Investing.com Nigeria 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 10
Analyst action 4
Regulatory and legal 3
Deals and strategy 3
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Market source Direct company coverage

Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?

Neurocrine Biosciences (NBIX) shows strong potential for continued stock growth due to its remarkably improving earnings outlook. Analysts are consistently raising earnings estimates for the biopharmaceutical company, indicating growing optimism. This positive trend in revisions,

Tone
Positive 75/100
Event
Earnings
Published
14 Jul 2026 16:13
Source
Market source
Investing.com Nigeria Direct company coverage

Form 4 Neurocrine Biosciences Inc For: 13 July By Investing.com

This article from Investing.com is a standard Form 4 filing for Neurocrine Biosciences Inc (NBIX) as of July 13. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders.

Tone
Negative 40/100
Event
Market update
Published
14 Jul 2026 01:11
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Neurocrine Biosciences chief legal officer sells $1.79m in stock By Investing.com

Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences (NASDAQ:NBIX), sold 10,000 shares for $1.79 million and simultaneously acquired 10,000 shares for $814,900 through option exercise on July 9, 2026. This transaction occurred while the stock was near its 52-week high, a

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:32
Source
Investing.com Nigeria
Stock Titan Direct company coverage

[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity

Neurocrine Biosciences Inc.'s Chief Legal Officer, Darin Lippoldt, reported an open-market sale of 10,000 shares of common stock at a weighted average price of $179.6014 per share, executed under a pre-arranged Rule 10b5-1 trading plan. On the same day, Lippoldt exercised non-qua

Tone
Negative 41/100
Event
Market update
Published
13 Jul 2026 21:11
Source
Stock Titan
Investing.com Direct company coverage

Neurocrine Biosciences chief legal officer sells $1.79m in stock

Darin Lippoldt, Chief Legal Officer at Neurocrine Biosciences, sold 10,000 shares of common stock for $1.79 million on July 9, 2026, through a pre-planned trading arrangement, while the stock trades near its 52-week high. Prior to this sale, Lippoldt acquired 10,000 shares by exe

Tone
Positive 64/100
Event
Market update
Published
13 Jul 2026 20:13
Source
Investing.com
Stock Titan Direct company coverage

Neurocrine Biosciences (NBIX) officer exercises options, sells 4,367 shares

Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, executed an options exercise and stock sale. She acquired 4,367 shares at $106.02 per share and simultaneously sold them at an average price of $181.02 per share through a pre-arranged Rule 10b5-1 trading plan. Foll

Tone
Neutral 50/100
Event
Regulatory and legal
Published
13 Jul 2026 20:11
Source
Stock Titan
Investing.com Direct company coverage

Truist raises Neurocrine Bio stock price target on pipeline potential

Truist Securities has increased its price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX) shares to $200 from $155, maintaining a Buy rating, due to strong pipeline potential and expected Q2 2026 results beating expectations. The firm anticipates a fiscal year 2026 guidance

Tone
Positive 71/100
Event
Analyst action
Published
13 Jul 2026 12:41
Source
Investing.com
Simply Wall Street Direct company coverage

Neurocrine Biosciences (NBIX) Posts Strong Q1 Results, Is More Upside Still Left?

Neurocrine Biosciences (NBIX) reported strong Q1 2026 results with over US$800 million in net product sales, driven by INGREZZA, leading to significant institutional interest and a 37.41% share price return over 90 days. Despite this surge, Simply Wall St's narrative valuation su

Tone
Positive 76/100
Event
Earnings
Published
11 Jul 2026 08:11
Source
Simply Wall Street
Stock Titan Direct company coverage

[144] NEUROCRINE BIOSCIENCES INC SEC Filing

Neurocrine Biosciences (NBIX) filed a Form 144 indicating an affiliate plans to sell 4,367 shares of common stock on 07/10/2026, valued at $788,461.85, connected to the exercise of stock options. This filing also details prior Rule 10b5-1 sales by Ingrid Delaet, including 8,433 s

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:41
Source
Stock Titan
Sahm Direct company coverage

Neurocrine Biosciences (NBIX) Stock Looks Reasonable After Its 90% Run

After a significant 90% return over the past five years, Neurocrine Biosciences (NBIX) appears to be trading near its fair value rather than offering a clear bargain. The stock's current P/E ratio of 26.8x is higher than the biotech industry average but aligns closely with its ta

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 06:41
Source
Sahm
Simply Wall Street Direct company coverage

Did Neurocrine’s (NBIX) CRENESSITY Push Into Infants Just Recast Its Rare-Disease Strategy?

Neurocrine Biosciences has launched a Phase 2 study for CRENESSITY in infants, signaling a strategic push into younger pediatric patients with congenital adrenal hyperplasia, a group with no approved therapies. While this move could broaden CRENESSITY’s market, the company's fina

Tone
Positive 64/100
Event
Market update
Published
10 Jul 2026 02:39
Source
Simply Wall Street
Investing.com Canada Direct company coverage

Neurocrine Biosciences chief regulatory officer sells $2.6m stock By Investing.com

Ingrid Delaet, Chief Regulatory Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), sold approximately $2.6 million worth of common stock between July 7 and July 9, 2026, following the exercise of stock options. The sales were conducted through a Rule 10b5-1 trading plan, with

Tone
Positive 58/100
Event
Regulatory and legal
Published
09 Jul 2026 22:39
Source
Investing.com Canada
Investing.com Canada Direct company coverage

Form 4 Neurocrine Biosciences Inc For: 9 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Neurocrine Biosciences Inc. with the filing date of July 9. Form 4s are SEC filings used to report changes in beneficial ownership of securities by company insiders. The article notes that Neurocrine Biosciences Inc.

Tone
Positive 60/100
Event
Market update
Published
09 Jul 2026 22:39
Source
Investing.com Canada
Stock Titan Direct company coverage

Neurocrine (NBIX) officer sells 14,571 shares under Rule 10b5-1 plan

Ingrid Delaet, Neurocrine Biosciences' Chief Regulatory Officer, exercised stock options for 14,571 shares and subsequently sold them in open-market transactions between July 7-9, 2026. The sales, executed under a pre-arranged Rule 10b5-1 trading plan, netted approximately $2.60

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Jul 2026 22:39
Source
Stock Titan
Aspen Daily News Direct company coverage

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

Neurocrine Biosciences, Inc. announced its second quarter 2026 financial results conference call and webcast will take place on July 30, 2026, at 1:30 p.m. Pacific Time. The press release will be issued at 1:00 p.m. PT on the same day. Details for dial-in and webcast access are p

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 19:40
Source
Aspen Daily News
Stock Titan Direct company coverage

Neurocrine's July 30 earnings call is scheduled for 4:30 p.m. ET

Neurocrine Biosciences (Nasdaq: NBIX) will release its second-quarter 2026 financial results on July 30, 2026, followed by a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET). The company noted that past similar announcements have typically coincided with small positive

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 19:39
Source
Stock Titan
TradingView Direct company coverage

ETFs Investing in Neurocrine Biosciences, Inc. Stocks

This article lists various ETFs that include Neurocrine Biosciences, Inc. (1NBIX) stocks in their holdings. The ETFs are sorted by market value and include details such as asset manager, management style, expense ratio, AUM, and price performance. This information aims to help in

Tone
Positive 62/100
Event
Market update
Published
09 Jul 2026 07:39
Source
TradingView
Market source Direct company coverage

Neurocrine Biosciences (NBIX) Stock Looks Fair On Earnings But Pricey Versus Biotechs

Neurocrine Biosciences stock, despite a strong five-year run, appears fairly valued on earnings but expensive compared to the broader biotech sector. The company's P/E ratio is higher than industry averages, though it's close to its implied fair P/E, suggesting the market has alr

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 22:14
Source
Market source
Stock Titan Direct company coverage

Insider option exercise and 10b5-1 sales at NBIX (NBIX)

Ingrid Delaet, an insider at Neurocrine Biosciences (NBIX), executed an option exercise for 14,571 shares on July 7, 2026, which was paid in cash. This transaction was accompanied by earlier, pre-scheduled 10b5-1 sales of 2,261 shares on May 29, 2026, generating $354,321.31. The

Tone
Neutral 50/100
Event
Balance sheet
Published
07 Jul 2026 20:11
Source
Stock Titan